![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PDZRN4 |
Gene summary for PDZRN4 |
![]() |
Gene information | Species | Human | Gene symbol | PDZRN4 | Gene ID | 29951 |
Gene name | PDZ domain containing ring finger 4 | |
Gene Alias | LNX4 | |
Cytomap | 12q12 | |
Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | B4DGD1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
29951 | PDZRN4 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.88e-04 | 1.77e-01 | 0.0155 |
29951 | PDZRN4 | HTA11_347_2000001011 | Human | Colorectum | AD | 3.59e-03 | 1.74e-01 | -0.1954 |
29951 | PDZRN4 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.27e-03 | 1.61e-01 | -0.1207 |
29951 | PDZRN4 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.66e-04 | 1.46e-01 | -0.1464 |
29951 | PDZRN4 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.94e-04 | 2.35e-01 | -0.059 |
29951 | PDZRN4 | HTA11_2992_2000001011 | Human | Colorectum | SER | 1.25e-03 | 3.90e-01 | -0.1706 |
29951 | PDZRN4 | HTA11_546_2000001011 | Human | Colorectum | AD | 7.42e-04 | 2.15e-01 | -0.0842 |
29951 | PDZRN4 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.33e-82 | 3.95e+00 | 0.281 |
29951 | PDZRN4 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.21e-19 | 5.26e-01 | 0.3005 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | ![]() |
Oral cavity | LP | ![]() |
Oral cavity | EOLP | ![]() |
Oral cavity | NEOLP | ![]() |
Esophagus | HGIN | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PDZRN4 | SNV | Missense_Mutation | rs140551427 | c.1262N>A | p.Arg421Gln | p.R421Q | Q6ZMN7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A0CW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
PDZRN4 | SNV | Missense_Mutation | rs755317185 | c.725N>A | p.Arg242Gln | p.R242Q | Q6ZMN7 | protein_coding | deleterious_low_confidence(0.03) | benign(0.007) | TCGA-A2-A0T7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PDZRN4 | SNV | Missense_Mutation | c.2429N>A | p.Val810Asp | p.V810D | Q6ZMN7 | protein_coding | tolerated(0.63) | benign(0.046) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
PDZRN4 | SNV | Missense_Mutation | novel | c.2330N>T | p.Ala777Val | p.A777V | Q6ZMN7 | protein_coding | tolerated(0.13) | benign(0.005) | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR |
PDZRN4 | SNV | Missense_Mutation | novel | c.31N>T | p.Ala11Ser | p.A11S | Q6ZMN7 | protein_coding | tolerated_low_confidence(0.15) | unknown(0) | TCGA-AC-A3QP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
PDZRN4 | SNV | Missense_Mutation | c.2278N>A | p.Leu760Ile | p.L760I | Q6ZMN7 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PDZRN4 | SNV | Missense_Mutation | novel | c.2825N>T | p.Ser942Ile | p.S942I | Q6ZMN7 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PDZRN4 | SNV | Missense_Mutation | rs772824285 | c.2582N>A | p.Ser861Tyr | p.S861Y | Q6ZMN7 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-E9-A1NC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
PDZRN4 | SNV | Missense_Mutation | c.1965N>A | p.Asn655Lys | p.N655K | Q6ZMN7 | protein_coding | tolerated(0.05) | benign(0.096) | TCGA-E9-A295-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
PDZRN4 | SNV | Missense_Mutation | c.1795N>A | p.Glu599Lys | p.E599K | Q6ZMN7 | protein_coding | deleterious(0.04) | benign(0.164) | TCGA-EW-A1OV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | epirubicin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |